[1] HF McFarland & R Martin, “Multiple sclerosis: a complicated picture of autoimmunity”, Nature Immunology 8, 913 – 919 (2007)
[2] Abhijit Chaudhuri & Peter O. Behan, “Multiple Sclerosis Is Not an Autoimmune Disease”, Arch Neurol /Vol 61, Oct 2004
[3] Adams RD. “Chapter 5: A comparison of the morphology of the human demyelinating diseases and experimental allergic encephalomyelitis”, In: Kies MW, Alvord EC, eds. Allergic encephalomyelitis. Springfield, Ill: Charles C Thomas, 1959;183-209.
[4] Behan PO, Geshwind N, Lamarche JB, et al. “Delayed hypersensitivity to encephalitogenic protein in disseminated encephalitis”, Lancet. 1968;2:1009-1012.
[5] Behan PO, Kies MW, Lisak RP, et al. “Immunologic mechanisms in in experimental encephalomyelitis in non-human primates”, Arch Neurol. 1973;29:4-9.
[6] “Acute Disseminated Encephalomyelitis (ADEM)”, www.adem.org
[7] A Compston FRCP, A Coles, “Multiple sclerosis”, Lancet 2002; 359: 1221–31
[8] Behan PO, Chaudhuri A, Roep BO, “The pathogenesis of multiple sclerosis revisited”, J R Coll Physicians Edinb. 2002;32:244-265.
[9] Barnett MH, Prineas JW, “Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion”, Ann Neurol 2004; 55: 458-468.
[10] Ralf-Björn Lindert1et al, “Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein”, Brain (1999) 122 (11): 2089-2100
[11] Marshall BJ, Warren JR. “Unidentified curved bacillus on gastric epithelium in active chronic gastritis”, Lancet 1983;1(8336):1273-1275.
[12] The IFNB Multiple Sclerosis Study Group, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial”, Neurology 1993 Apr; 43(4) : 655-61
[13] DH Miller et al for the International Natalizumab Multiple Sclerosis Trial Group, “A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis”, N Engl J Med 2003; 348:15-23
[14] J Sun et al, “T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis”, The Journal of Immunology March 1, 1991 vol. 146 no. 5 1490-1495
[15] Helen Briggs interviewing Alistair Compston on BBC website, “Genetic clues to what triggers MS”, http://www.bbc.co.uk/news/health-14475497
[16] International Multiple Sclerosis Genetics Consortium, “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis”, Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.
[17] Krisha McCoy, “Women and Autoimmune Disorders”, http://www.everydayhealth.com/autoimmune-disorders/understanding/women-and-autoimmune-diseases.aspx
[18] Ciccarelli O et al, “A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging–evidence of Wallerian degeneration”, J Neurol. 2003 Mar;250(3):287-92.
[19] Jones JL, Coles AJ, “Campath-1H treatment of multiple sclerosis”, Neurodegener Dis. 2008;5(1):27-31.
[20] Barnett MH, Sutton I, “The pathology of multiple sclerosis: a paradigm shift”, Curr Opin Neurol. 2006 Jun;19(3):242-7.
[21] Khadir Raddassi et al, “Increased Frequencies of Myelin Oligodendrocyte Glycoprotein/MHC Class II-Binding CD4 Cells in Patients with Multiple Sclerosis”, The Journal of Immunology July 15, 2011 vol. 187 no. 2 1039-1046
[22] N Grigoriadis et al, “Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction”, Clinical Neurology and Neurosurgery 108 (2006) 241–244
[23] N Grigoriadis and G Hadjigeorgiou, “Virus-mediated autoimmunity in Multiple Sclerosis”, Journal of Autoimmune Diseases 2006, 3:1